Short communication
Hedvig Bölcskei
Abstract
Depression is a common mental disease, which affects 6-7% of the population. Major depressive disorder is treated by talk therapy or medication, usually by antidepressants which are either serotonin selective reuptake inhibitors (SSRI) like fluoxetine and paroxetine, or by serotonin and norepinephrine reuptake inhibitors (SNRI) like duloxetine and venlafaxine. Because of the well-known slow onset and side effects of the antidepressants, there is an unmet medical need for further efficient drugs with more advantageous side effect profiles. Some antidepressants, (e.g. trazodone, nefazodone, mianserin, mirtazapine) act both as SERT inhibitors and 5-HT2C antagonists. The suggestion arose that the compounds with dual activities might be advantageous. The design and synthesis of dually active compounds are more difficult processes than the design and synthesis of selective inhibitors. Éliás and coworkers developed various types of hybrid compounds with serotonin transporter inhibitor (SERT) and serotonin 5-HT2C receptor antagonist activities [O.Éliás et al. Bioorg. Med. Chem. Lett.24, 2118 (2014), ibid 26, 914 (2016)]. We have synthesized a compound family with substituted phenoxy-benzylamine moieties. Our novel compounds showed excellent rSERT Ki and r5-HT2C Ki values and advantageous physico-chemical properties (clogP, solubility). A few structure-activity relationships (SAR) have also been established.